Legal Wisdom
Partner with us

Litigation Intel

Hair Relaxer / Uterine Cancer

Users of chemical hair relaxers allege the products caused uterine cancer, ovarian cancer and fibroids, with cases consolidated in an Illinois MDL.

Composite score
75
Scored Oct 26, 8:01 AM

The litigation is moving forward through coordinated pretrial proceedings with set bellwether trial dates, supported by active legal advertising and expanding toxicological research.

Score breakdown

Four dimensions, each 0-100, generated by AI from the recent signal feed plus general knowledge of the tort.

Momentum78

Bellwether trial dates have been set for late 2027, while reports indicate major defendants are exploring options to address their chemical liabilities.

Science75

Epidemiological research linking endocrine-disrupting chemicals to uterine and ovarian cancers continues to be supplemented by new laboratory toxicity and demographic disparity studies.

Campaign88

Plaintiff law firms maintain widespread advertising campaigns and aggressive client intake efforts targeting women diagnosed with hormone-sensitive reproductive cancers.

Litigation stage60

The multidistrict litigation remains in mid-stage proceedings, with ongoing discovery and the inaugural bellwether trial officially scheduled for September 2027.

Scores are generated by AI from public sources for market research. They are not legal advice or a prediction of any outcome.

Buying cases in this litigation?

We can launch an exclusive campaign to your intake criteria within one week.

Partner with us

Signal feed

4 recent signals across news, FDA, PubMed, and court sources.

← Back to all torts